To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Validation of a new assay… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Validation of a new assay for α-synuclein detection in cerebrospinal fluid.

Journal article
Authors Marthe Gurine Førland
Annika Öhrfelt
Linn Silje Oftedal
Ole-Bjørn Tysnes
Jan Petter Larsen
Kaj Blennow
Henrik Zetterberg
Guido Alves
Johannes Lange
Published in Clinical chemistry and laboratory medicine
Volume 55
Issue 2
Pages 254–260
ISSN 1437-4331
Publication year 2017
Published at Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 254–260
Language en
Subject categories Neurochemistry


Abnormal α-synuclein aggregation and deposition is the pathological hallmark of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), but is also found in Alzheimer disease (AD). Therefore, there is a gaining interest in α-synuclein in cerebrospinal fluid (CSF) as potential biomarker for these neurodegenerative diseases. To broaden the available choices of α-synuclein measurement in CSF, we developed and validated a new assay for detecting total α-synuclein.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?